eMedicine Specialties > Dermatology > Pediatric Diseases

Erythema Toxicum Neonatorum

Author: Trisha C Beute, MD, Staff Physician, Department of Dermatology, Naval Medical Center, Portsmouth
Coauthor(s): Neil F Gibbs, MD, Voluntary Associate Professor, Departments of Pediatrics and Medicine, University of California, San Diego School of Medicine; Assistant Chair, Program Director, Pediatric Dermatologist, Department of Dermatology, Naval Medical Center, San Diego; Robert Huff, MD, Dermatology, Inc, ; Eleanor E Sahn, MD, Director, Division of Pediatric Dermatology, Associate Professor, Departments of Dermatology and Pediatrics, Medical University of South Carolina
Contributor Information and Disclosures

Updated: Jun 18, 2009

Introduction

Background

Erythema toxicum neonatorum (ETN) is a benign self-limited eruption occurring primarily in healthy newborns in the early neonatal period. Erythema toxicum neonatorum is characterized by macular erythema, papules, vesicles, and pustules, and it resolves without permanent sequelae.1 Also see the eMedicine Pediatrics article, Erythema Toxicum.

Pathophysiology

Increased levels of immunological and inflammatory mediators (eg, interleukins 1 and 8, eotaxin, the adhesion molecule E-selectin, the water-channel proteins aquaphorin 1 and aquaphorin 3, the chemotactic factor psoriasin, high-mobility group box chromosomal protein 1, nitric oxide and its isoforms, the antimicrobial peptide LL-37) suggest that erythema toxicum neonatorum may be an immune system reaction.2,3,4 The location of erythema toxicum neonatorum to primarily hair-bearing areas suggests that the hair follicle may be involved. Additionally, the number of mast cells is increased around hair follicles in involved skin.5

The eosinophilic infiltrate of erythema toxicum neonatorum suggests an allergic- or hypersensitivity-related etiology, but no allergens have been identified. Newborn skin appears to respond to any injury with an eosinophilic infiltrate. Because erythema toxicum neonatorum is rarely seen in premature infants, it is believed that mature newborn skin is required to produce this reaction pattern.6

Contactants and mechanical irritation have been considered and rejected as etiologies.

Frequency

International

Erythema toxicum neonatorum occurs in one third to one half of full-term infants and in 5% of premature infants.

Mortality/Morbidity

Erythema toxicum neonatorum is a self-limited eruption that resolves spontaneously. Although one study found that infants with erythema toxicum neonatorum had an increased risk of atopy,7 subsequent studies have failed to support this finding.

Race

No racial or ethnic predisposition is known.

Sex

The prevalence is higher in males (55%) than in females (30%),8 except among females born of first pregnancies, who have a higher rate than males of first pregnancies.

Age

  • Erythema toxicum neonatorum presents within the first 4 days of life in full-term infants, with the peak onset occurring within the first 48 hours following birth. Rare cases have been reported at birth.9,10
  • Incidence rises with increasing gestational age and birth weight.
  • Delayed onset rarely may occur in full-term and preterm infants up to age 14 days.11,12

Clinical

History

When evaluating for erythema toxicum neonatorum (ETN), focus the history on age at onset of the eruption, absence of systemic signs (eg, fever, irritability, lethargy, mucocutaneous involvement), or maternal history of herpes simplex/varicella viral infection, bacterial pyoderma, or candidiasis.

  • Infants with erythema toxicum neonatorum otherwise are healthy and lack systemic symptoms.
  • The eruption is self-limited with most cases resolving within 5-14 days without residual sequelae.
  • Recurrences are uncommon but have been reported up to the sixth week of life. They tend to be mild in severity.

Physical

Focus the physical examination on location, size, and distribution of macules, wheals, papules, and pustules on the skin. Note the absence of mucosal, palmar, or plantar involvement. Signs of systemic toxicity, including hypothermia or hyperthermia, lethargy, and irritability, are not associated with erythema toxicum neonatorum.

  • Erythema toxicum neonatorum most commonly presents with a blotchy, evanescent, macular erythema, often on the face or trunk.
  • The macules are irregular, blanchable, and vary in size.
  • In more severe cases, pale yellow or white wheals or papules on an erythematous base may follow. In approximately 10% of patients, 2-4 mm pustules develop.
  • Numbers and distribution of lesions vary from a few and widely scattered to numerous and extensive.
  • Sites of predilection include the forehead, face, trunk, and proximal extremities, but lesions may occur anywhere, including the genitalia.13 Involvement of the mucous membranes and palms and soles rarely occurs.

Causes

The cause of erythema toxicum neonatorum is unknown. Multiple theories have been proposed to explain this common disorder.

  • Neonates have an increased number of hair follicles compared with adults, and the occurrence of erythema toxicum neonatorum in non–hair-bearing areas such as palms and soles is rare. Inflammatory cells tend to concentrate around hair follicles, and coccilike microbes have been demonstrated in the follicular epithelium and inside the inflammatory cells. This suggests that erythema toxicum neonatorum may be a response to microbes that have penetrated the hair follicle. This process may possibly be integral in developing the new immune system.14
  • The high frequency of eosinophilia suggests an allergic basis, leading some authors to suggest that erythema toxicum neonatorum may be an immediate hypersensitivity reaction to a substance passed from the mother transplacentally; however, convincing support is lacking for this theory.15
  • No responsible exotoxin, allergen, component of sebum, or infectious agent has been linked credibly to erythema toxicum neonatorum.
  • Medications administered to newborns and the mode of feeding have no effect on incidence.
  • Other proposed theories include a transient adjustment reaction of the skin to mechanical or thermal stimulation or an acute graft-versus-host reaction induced by the maternal-fetal transfer of lymphocytes before or during delivery.16 Analysis of skin samples of 2 male patients with erythema toxicum neonatorum did not support a graft-versus-host reaction because no maternal cells were found in the samples using fluorescence in situ hybridization identification of cells with 2 XX chromosomes.17
  • Risk factors include birth in hot wet climates, being fed on a mixed diet or milk-powder substitute, and being born via vaginal delivery. A positive correlation has been recognized between the length of labor and both the incidence of erythema toxicum neonatorum and the duration of the cutaneous manifestations.8

More on Erythema Toxicum Neonatorum

Overview: Erythema Toxicum Neonatorum
Differential Diagnoses & Workup: Erythema Toxicum Neonatorum
Treatment & Medication: Erythema Toxicum Neonatorum
Follow-up: Erythema Toxicum Neonatorum
References

References

  1. Schwartz RA, Janniger CK. Erythema toxicum neonatorum. Cutis. Aug 1996;58(2):153-5. [Medline].

  2. Marchini G, Hultenby K, Nelson A, et al. Increased expression of HMGB-1 in the skin lesions of erythema toxicum. Pediatr Dermatol. Sep-Oct 2007;24(5):474-82. [Medline].

  3. Marchini G, Lindow S, Brismar H, et al. The newborn infant is protected by an innate antimicrobial barrier: peptide antibiotics are present in the skin and vernix caseosa. Br J Dermatol. Dec 2002;147(6):1127-34. [Medline].

  4. Marchini G, Stabi B, Kankes K, Lonne-Rahm S, Ostergaard M, Nielsen S. AQP1 and AQP3, psoriasin, and nitric oxide synthases 1-3 are inflammatory mediators in erythema toxicum neonatorum. Pediatr Dermatol. Sep-Oct 2003;20(5):377-84. [Medline].

  5. Nelson A, Ulfgren AK, Edner J, Stabi B, Brismar H, Hultenby K. Urticaria Neonatorum: accumulation of tryptase-expressing mast cells in the skin lesions of newborns with Erythema Toxicum. Pediatr Allergy Immunol. Dec 2007;18(8):652-8. [Medline].

  6. Carr JA, Hodgman JE, Freedman RI, Levan NE. Relationship between toxic erythema and infant maturity. Am J Dis Child. Aug 1966;112(2):129-34. [Medline].

  7. Singh M, Arora NK, Sroa HS. Urticaria neonatorum--an earliest marker of atopy. Indian J Med Res. Feb 1980;71:273-7. [Medline].

  8. Liu C, Feng J, Qu R, et al. Epidemiologic study of the predisposing factors in erythema toxicum neonatorum. Dermatology. 2005;210(4):269-72. [Medline].

  9. Levy HL, Cothran F. Erythema toxicum neonatorum present at birth. Am J Dis Child. Apr 1962;103:617-9. [Medline].

  10. Marino LJ. Toxic erythema present at birth. Arch Dermatol. Oct 1965;92(4):402-3. [Medline].

  11. Akoglu G, Ersoy Evans S, Akca T, Sahin S. An unusual presentation of erythema toxicum neonatorum: delayed onset in a preterm infant. Pediatr Dermatol. May-Jun 2006;23(3):301-2. [Medline].

  12. Chang MW, Jiang SB, Orlow SJ. Atypical erythema toxicum neonatorum of delayed onset in a term infant. Pediatr Dermatol. Mar-Apr 1999;16(2):137-41. [Medline].

  13. Maffei FA, Michaels MG, Wald ER. An unusual presentation of erythema toxicum scrotal pustules present at birth. Arch Pediatr Adolesc Med. Jun 1996;150(6):649-50. [Medline].

  14. Marchini G, Nelson A, Edner J, Lonne-Rahm S, Stavreus-Evers A, Hultenby K. Erythema toxicum neonatorum is an innate immune response to commensal microbes penetrated into the skin of the newborn infant. Pediatr Res. Sep 2005;58(3):613-6. [Medline].

  15. Keitel HG, Yadav V. Etiology of toxic erythema. Erythema toxicum neonatorum. Am J Dis Child. Sep 1963;106:306-9. [Medline].

  16. Bassukas ID. Is erythema toxicum neonatorum a mild self-limited acute cutaneous graft-versus-host-reaction from maternal-to-fetal lymphocyte transfer?. Med Hypotheses. Aug 1992;38(4):334-8. [Medline].

  17. Droitcourt C, Khosrotehran K, Halaby E, Aractingi S. Maternal cells are not responsible [corrected] for erythema toxicum neonatorum [corrected]. Pediatr Dermatol. May-Jun 2008;25(3):411-3. [Medline].

  18. Ferrandiz C, Coroleu W, Ribera M, Lorenzo JC, Natal A. Sterile transient neonatal pustulosis is a precocious form of erythema toxicum neonatorum. Dermatology. 1992;185(1):18-22. [Medline].

  19. Van Praag MC, Van Rooij RW, Folkers E, Spritzer R, Menke HE, Oranje AP. Diagnosis and treatment of pustular disorders in the neonate. Pediatr Dermatol. Mar-Apr 1997;14(2):131-43. [Medline].

  20. Freeman RG, Spiller R, Knox JM. Histopathology of erythema toxicum neonatorum. Arch Dermatol. Oct 1960;82:586-9. [Medline].

  21. Luders D. Histologic observations in erythema toxicum neonatorum. Pediatrics. Aug 1960;26:219-24. [Medline].

  22. Marchini G, Ulfgren AK, Lore K, Stabi B, Berggren V, Lonne-Rahm S. Erythema toxicum neonatorum: an immunohistochemical analysis. Pediatr Dermatol. May-Jun 2001;18(3):177-87. [Medline].

Further Reading

Keywords

erythema toxicum neonatorum, erythema neonatorum, toxic erythema, erythema neonatorum allergicum, erythema papulosum, urticaria neonatorum, erythema dyspepsicum

Contributor Information and Disclosures

Author

Trisha C Beute, MD, Staff Physician, Department of Dermatology, Naval Medical Center, Portsmouth
Trisha C Beute, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Coauthor(s)

Neil F Gibbs, MD, Voluntary Associate Professor, Departments of Pediatrics and Medicine, University of California, San Diego School of Medicine; Assistant Chair, Program Director, Pediatric Dermatologist, Department of Dermatology, Naval Medical Center, San Diego
Neil F Gibbs, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, and Society for Pediatric Dermatology
Disclosure: Nothing to disclose.

Robert Huff, MD, Dermatology, Inc, 
Robert Huff, MD, Dermatology, Inc is a member of the following medical societies: American Academy of Dermatology and Phi Beta Kappa
Disclosure: Nothing to disclose.

Eleanor E Sahn, MD, Director, Division of Pediatric Dermatology, Associate Professor, Departments of Dermatology and Pediatrics, Medical University of South Carolina
Eleanor E Sahn, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Southern Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Eleanor E Sahn, MD, Director, Division of Pediatric Dermatology, Associate Professor, Departments of Dermatology and Pediatrics, Medical University of South Carolina
Eleanor E Sahn, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Southern Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Van Perry, MD, Assistant Professor, Department of Medicine, Division of Dermatology, University of Texas Health Science Center
Van Perry, MD is a member of the following medical societies: American Academy of Dermatology and American Society for Laser Medicine and Surgery
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.